Cardiovascular Implantable Electronic Devices (CIEDs) are life-saving marvels of modern medicine. However, with over 300,000 patients receiving a new CIED implantation annually in the US alone, there has been a simultaneous surge in device infections. These infections can lead to substantial morbidity, with infected patients facing over 3-fold higher mortality compared to those without infections. Moreover, the financial burden on the healthcare system is significant.
The efficacy of antibiotics as a standalone treatment for CIED infection is limited. These factors have the potential to result in increased rates of infection relapse and fatality. In patients diagnosed with a definite CIED infection, the recommended course of action is the comprehensive extraction of both the device and lead. Research findings indicate that conducting extractions promptly following diagnosis leads to notable reductions in 1-year mortality rates, shorter durations of hospitalisation, and a decreased frequency of physician or hospital visits.
There are concerns about the lack of compliance with guidelines for removing hardware from patients with CIED infections. The goal of this analysis was to measure the number of Medicare beneficiaries with CIED-related infections. These patients had lead extraction procedures between 2007 and 2019. Additionally, the study attempted to analyse the resulting outcomes of these interventions. The researchers discovered that the process of lead extraction was linked to a decrease in mortality rates. Furthermore, they observed that conducting lead extraction at an earlier stage was correlated with even lower mortality rates compared to delaying the procedure.
This study identifies the need for comprehensive care in managing CIED infection. This includes identifying the infection, conducting a thorough examination, starting antibiotic treatment, making appropriate referrals, and deciding if extraction is needed. The study’s results highlight the urgent need to follow care guidelines more closely. They also stress the importance of improving quality within health systems.
💊 Could MFN Pricing Undermine Biosimilars?
MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.
Explore the risks and what stakeholders can do to protect market sustainability.
#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess
🔍 Are you prepared for the upcoming EU AI Act in healthcare?
As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.
Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!
#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation
💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?
A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.
Join the conversation on enhancing vaccination strategies for better health outcomes!
#SyenzaNews #Healthcare #HealthEconomics
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
